CommercialPrior AuthHigh impact
Prior authorization updates for Targeted Immunomodulators
Harvard Pilgrim Health Care·Dermatology, Rheumatology, Gastroenterology +1 more·Prior Authorization
Effective date
Jan 1, 2026
We identified it
Jun 20, 2026
Summary
Point32Health (Harvard Pilgrim, Tufts Health Plan) is implementing comprehensive prior authorization changes for targeted immunomodulator medications effective January 1, 2026. Key changes include new step therapy requirements (TNF inhibitors before JAK inhibitors), differentiated approval durations (6 months initial for dermatology vs 12 months for other conditions), stricter specialty provider requirements, and enhanced documentation requirements for moderate-to-severe disease criteria.
Action Required
Before January 1, 2026: Billing and clinical teams must update prior authorization workflows for all targeted immunomodulator medications. Update EMR templates to capture required documentation for moderate-to-severe disease criteria for psoriasis, psoriatic arthritis, and hidradenitis suppurativa. Implement step therapy protocols requiring TNF inhibitor trials before JAK inhibitors. Train staff on new approval duration timelines (6 months initial for dermatology, 12 months for non-dermatology indications). Review Point32Health provider website for updated medical necessity guidelines. Failure to follow new criteria will result in prior authorization denials.